Arm A | Arm B | ICER B/A | |
---|---|---|---|
Costs € / utility | Costs €/ utility | €/QALY | |
Base case | 27 734 €/0.51 | 31 688 €/ 0.52 | 395400 |
Utility of patients treated by erlotinib | |||
−20% (0.538) | 27 734 €/ 0.48 | 31 688 €/ 0.51 | 131800 |
−10% (0.606) | 27 734 €/0.51 | 31 688 €/ 0.52 | 395400 |
+10% (0.740) | 27 734 €/ 0.54 | 31 688 €/ 0.54 | NA |
+20% (0.807) | 27 734 €/ 0.57 | 31 688 €/ 0.55 | NA |
Post-progression cost | |||
1627 € | 25 954 €/ 0.51 | 28 787 €/ 0.52 | 283300 |
3021 € | 29 514 €/ 0.51 | 34 588 €/ 0.52 | 507400 |
Erlotinib tariff | |||
−30% | 24 282 €/ 0.51 | 29 788 €/ 0.52 | 550600 |
+ 30% | 31 186 €/ 0.51 | 33 588 €/ 0.52 | 240200 |